

# Quarterly Report

30 September 2010



# Letter to Our Stockholders

Dear Stockholders,

In the third quarter 2010, we were able to improve the good results of the previous quarter and consequently achieve a strong overall result in the first nine months. Not only the greatly increased business figures are currently convincing, but also and especially the good reception of our products on the market.

2

We are seeing that the market is honoring our product innovations and that there is strong demand for our complete range of products. This applies especially to our NEXUS / HIS on the German market. Following the order successes of the past months, the decision of the German military to award NEXUS the contract to equip the four military hospitals with NEXUS / HIS is another sign of the outstanding product position of NEXUS / HIS. This decision, which aroused a lot of attention, confirms to us that we have the right product strategy. We are convinced that we have achieved a very essential innovation in our sector with the conceptional approach and contents of NEXUS / HIS. The solution not only sets standards with respect to being state-of-the-art, but is also the most comprehensive product with respect to scope available on the German market in the meantime. NEXUS / HIS covers almost all hospital and administrative processes today, which can be supported digitally in hospitals. In this, we do not limit ourselves to the main processes such as surgical documentation and logistics, but also provide our customers with standardized depiction of special diagnostic processes on the basis of a uniform technology platform. In addition, we have been able to set a clear focal point with the requirement of „simplicity“ in designing the system, which is being well received on the market.

More very good news is that we are also successful in our other product areas and markets. This applies especially to the area of quality management in hospitals, a software product, which supports hospital knowledge management and which again more than 40 new customers decided to purchase in this year. We have also been able to record a considerable number of orders received in the pathology area. It is shown here that our new product generation NEXUS / PAS.Net can win substantial market shares thanks to intuitive user prompting. We have achieved good results on the Swiss market with our NEXUS / HIS solution in connection with NEXUS/HOSPIS software. We are especially expanding the cantonal-overlapping projects in St. Gallen, Fribourg, Lucerne and Aarau, which demonstrate the complete range of NEXUS / HIS solutions. We have also been able to win new projects in other foreign countries and consequently confirm our strategy of providing a high-quality international Hospital Information System. While we have been able to achieve encouraging development overall in this segment, we still have payment problems in one case, which we never experienced before in this form in German-speaking regions. We have taken preventive measures in this case.

The shortening of our project implementation times was another essential aspect of the third quarter. Our consistent orientation to reduced introduction times lets customers achieve the expected advantages of the software more quickly and at the same time means faster turnover for us. This applies not only to new customers, but is also very important in dealing with our regular customers. The topics of medication, emergency care as well as management and knowledge information systems are currently the focus of our regular customers and result in increased digitalization of customer hospital processes.

For this reason, the further development of our products will concentrate on optimizing the core hospital processes within NEXUS / HIS software. This includes the processes of „drug prescriptions“ and „medication administration“ as well as intensive care medicine and emergency care. We are especially focusing on the topic of management information systems, in which we have invested over the past months.

This overall very positive development can also be seen in the results of the first nine months 2009: We were again able to continue this positive development uninterrupted. Sales increased in the first nine months by approx. 11% from EUR 29.0 million to EUR 32.2 million, and the result before taxes improved by approx. 50% to EUR 2.48 million.

The result was approx. **EUR 2.51 million** following **EUR 1.37 million** and consequently we achieved an increase of **83 %**.

**The operative cash flow was again very positive. We achieved EUR 7.4 million following EUR 5.4 (Q3 2009) million previously.**

There were considerable changes in balance sheet positions compared to 31 December 2009. We adapted risk precautions with increased reserves and reduced our accounts payable at the same time. Our liquid assets (EUR 14.9 million) increased again thanks to the good result. Accounts payable decreased again compared to the first half year, but are slightly higher at 12.2 million than the value at the end of 2009 (EUR 12 million).

#### Highlights Q3 - 2010 Development of Business

- + Substantially increased sales
- + Comprehensive order of the German military for NEXUS / HIS
- + Strong demand for NEXUS/PAS.net

In spite of these good figures, the development of stock prices is sobering. After we saw very good results in the stock prices in the half-year result and the price increased to € 4.65 thanks to our business figures, this level declined substantially with fewer sales.

Despite this disappointing development of the stock price, we are pleased to be able to confirm the course of the business year until now and at the same time the long-term trend of our company with the current strong quarter. We have to build on this basis as a company and tackle the future shaping of the company and company strategy with a lot of self-confidence. We have the possibility here at NEXUS to shape a highly attractive company further and continue to grow in a highly attractive market.

Sincerley,



Dr. Ingo Behrendt  
CEO - NEXUS AG



# Innovations: New Solutions for Laboratories

Simplified and automated documentation obligations according to RiliBÄK are made possible with the software solution from NEXUS. The Vinzenz von Paul Hospitals in Stuttgart are reducing their workload substantially with this software.

4


The new guidelines of the German Medical Association concerning quality assurance of medical laboratory analyses - abbreviated as „RiliBÄK“ - has resulted in an enormous increase of administrative work in Germany laboratories over the past months. Laboratories have to document all procedure instructions - also called SOPs (Standard Operating Procedures) - and have them readily at hand. The work of updating these SOPs continually is hardly possible using conventional documentation procedures. Many hundreds of different SOPs, which have to be updated continually, represent a practically unsolvable challenge for the laboratories.

NEXUS has developed a solution within the context of its software-supported quality management systems and launched it on the market successfully, which provides substantial relief for the affected laboratories. The basis for the new solution is the established QM knowledge database NEXUS / CURATOR, which considerably simplifies creating a QM system in clinics and hospitable and „incidentally“ creates a bridgehead to the QM certification requirements. In the newly developed solution for laboratories, NEXUS / CURATOR generates all SOPs used for the analysis procedure at the push of a button without the user having to do anything else. To achieve this, data from the laboratory information system (LIS), the QM manual and the data specifications of the manufacturer are completely and automatically combined into an SOP and updated daily. If the data specifications change, a user or administrator does not need to intervene either; all new versions are created automatically and provided with corresponding version numbers. In addition, NEXUS / CURATOR ensures appropriate ISO routing of documents, an essential requirement for certification.

The automatically created SOPs can be retrieved from any workstation in a laboratory. Thanks to the possibility of decentralized updating with centralized provision of information, i.e., the decentralized updates are stored directly into a centralized knowledge database, the system fulfills all requirements of quality management and RiliBÄK.



Vinzenz von Paul Kliniken, Stuttgart




NEXUS / CURATOR: new solution for laboratory

**“NEXUS / CURATOR provided us with the solution to this urgent problem within a few days. As a result, the expected total workload was reduced by 90%. We comply with RiliBÄK and the requirements for certification with that and in addition now have access to the QM documents at all times and a good overview of revised QM documents.”**

Dr. Matthias Orth  
Medical Director – Institute for Laboratory Medicine

# NEXUS in the environment of Financial and Health markets



The course of the NEXUS share rose in the first 3 quarter 2010 quite continuously from 2,07 € to up-to-date approx. 3.90 €. In the meantime the course reached 4.65 € could not hold this level in the last weeks. The general upward tendency was however not broken thereby.

## Finance- and Event schedule 2010/11 (status quo: November '10)

### FINANCE SCHEDULE

German equity forum, Frankfurt (D)	22 - 24 November
Annual Report 2010	March 29th, 2011

### EVENT AND TRADE FAIR SCHEDULE

MEDICA, Düsseldorf (D)	17 - 20 November
DGPPN, Berlin (D)	24 - 27 November
KTQ-Forum, Berlin (D)	26 - 27 November

5

## Decisions for NEXUS-solutions 2010

- + Kliniken an der Paar, Aichach
- + Klinikum Bad Salzungen
- + Bundeswehrkrankenhaus, Berlin
- + Friedrich von Bodelschwingh - Klinik, Berlin
- + St. Josef-Hospital, Bochum
- + Zentrum für Radiologie und Nuklearmedizin, Dormagen
- + St.-Josefs-Hospital, Dortmund
- + Städtisches Krankenhaus, Eisenhüttenstadt
- + Kreiskrankenhaus Eschwege
- + Katholische Kliniken, Essen
- + Gemeinschaftspraxis für Pathologie, Fulda
- + Gelderland-Klinik, Geldern
- + Fachkrankenhaus Christophsbad, Göppingen
- + Kreiskrankenhaus Grevenbroich
- + Klinikum Gütersloh
- + Bundeswehrkrankenhaus, Hamburg
- + Fachklinik Dres. Denzel, Heilbronn
- + Bundeswehrzentralkrankenhaus, Koblenz
- + Gemeinschaftspraxis für Rad. und Nuklearmed., Cologne
- + Radiologie Köln-Kalk, Cologne
- + Gesellschaft für Parität. Sozialarbeit, Mainz
- + Krankenhaus Ludmillenstift, Meppen
- + Gemeinschaftspraxis für Pathologie, Mühlhausen
- + Rotkreuzklinikum, Munich
- + Ortenau Klinikum, Offenburg
- + St. Josefsklinik, Offenburg
- + Kreisklinik am Steinenberg, Reutlingen
- + Psychiatrisches Zentrum, Rickling
- + Klinikum Obergöltzsch, Rodewisch
- + Vinzenz von Paul Hospital, Rottweil
- + Pathologische Praxis, Spaichingen
- + Diakonie-Klinikum, Stuttgart
- + Gemeinschaftspraxis für Pathologie, Stuttgart
- + Sonnenberg-Klinik, Stuttgart
- + Vinzenz von Paul Kliniken - Marienhospital, Stuttgart
- + St. Anna Krankenhaus, Sulzbach-Rosenberg
- + Gesundheitszentrum, Treuchtlingen
- + Radiologische Praxis, Trier
- + Bundeswehrkrankenhaus, Ulm
- + Kliniken des Landkreises Weißenburg-Gunzenhausen
- + Klinikum Wels-Grieskirchen, Wels
- + Lahn-Dill-Kliniken, Wetzlar
- + Missionsärztliche Klinik, Würzburg
- + Diakoniewerk, Zschadraß
- + Kardinal Schwarzenberg'sches Krankenhaus, Schwarzach (A)
- + AZ Ziekenhuis St.-Dimpna, Geel (BE)
- + Centre Hospitalier de Mouscron, Mouscron (BE)
- + Hôpital Cantonal, Fribourg (CH)
- + Kantonsspital Liestal (CH)
- + Hôpital Psychiatrique Cantonal de Marsens, Marsens (CH)
- + Spital STS AG, Thun (CH)
- + Dronning Ingrid's Hospital, Nuuk (DK)
- + Hospital Hispania, Madrid (ES)
- + Hospital Clinico Universitario de Valladolid, Valladolid (ES)
- + Benghazi Medical Center, Benghazi (LY)
- + Sykehuset Innlandet, Gjøvik (NO)
- + Rikshospitalet, Oslo (NO)
- + St. Olavs Hospital, Trondheim (NO)

# Sales Increase

## in the 3rd Quarter

During the first three quarters of 2010, the group sales of the NEXUS-Group were increased by 10.8 % from KEUR 29,030 to KEUR 32,160.


Once more, the strong sales increase was down to segment „**Healthcare Software**“. Here, sales rose year on year from KEUR 25,765 to **KEUR 28,782 (+ 11.7 %)**. The good development was due to the introduction of numerous new software products and increased sales to existing customers.

**6** At **KEUR 3,378** (previous year KEUR 3,265), the sales of the „**Healthcare Service**“ segment were higher than last year's figure (+ 3.5 %). Here, the targets were achieved.

During the **third quarter**, total **sales of KEUR 11,429** were achieved, therefore approx. 12.0 % more than in the previous year. This means that the Healthcare Software segment achieved an increase of 12.9 % from 9,098 (Q3-2009) to KEUR 10,272 (Q3-2010), while the Healthcare Service segment achieved 4.9 % higher sales of KEUR 1,157 (Q3-2009: KEUR 1.103).

The **proportion of sales abroad** was **37.8 %** for the key date and was therefore at the level of the previous year (35.5 %). The continuing high proportion of sales in the international market is due mainly to projects in **America, Northern Europe and Switzerland**.

**One point to be mentioned specifically with respect to the first 9 months is the increase in sales in the area of Hospital Information Systems (HIS) in Germany and in Switzerland.**



Sales by regions	01/01/ -	01/01/ -	Δ in %	01/07/ -	01/07/ -	Δ in %
	30/09/09	30/09/10		30/09/09	30/09/10	
	KEUR	KEUR		KEUR	KEUR	
Germany	18,724	19,978	6.7	6,625	7,241	9.3
Switzerland	6,946	9,629	38.6	2,716	3,975	46.4
Austria	651	894	37.3	222	303	36.5
Italy	141	17	-87.9	66	5	-92.4
Rest on Europe / USA	1,160	1,642	41.6	24	-95	-495.8
Arabian region	1,408			548		
<b>Total</b>	<b>29,030</b>	<b>32,160</b>	<b>10.8</b>	<b>10,201</b>	<b>11,429</b>	<b>12.0</b>

### Highlights Q3 - 2010 Group sales and Result

- + 10.8 % increase in sales to EUR 32.2 million
- + 11.7 % increase in sales in segment Healthcare Software to EUR 28.8 million
- + Increase in EBITDA by 20.1 % to EUR 6.5 million
- + Operative Cash Flow increased by 62.2 % to KEUR 7,363

Sales by divisions	01/01/ -	01/01/ -	Δ in %	01/07/ -	01/07/ -	Δ in %
	30/09/09	30/09/10		30/09/09	30/09/10	
	KEUR	KEUR		KEUR	KEUR	
Healthcare Software	25,765	28,782	11.7	9,098	10,272	12.9
Healthcare Service	3,265	3,378	3.5	1,103	1,157	4.9
<b>Total</b>	<b>29,030</b>	<b>32,160</b>	<b>10.8</b>	<b>10,201</b>	<b>11,429</b>	<b>12.0</b>

# Results in the First three Quarters 2010

The profit key figures developed positively throughout the first three quarters. The group results before tax increased by around 49.7 % to KEUR 2,476 during this period (Q3 2009 KEUR 1,655).


The **EBITDA** reached **KEUR 6,468 (+ 20.1 %)** compared to 5,381 (Q3 2009). By tax receipts within the latent taxes of KEUR 86 the tax result with KEUR 34 became positive. The result after taxes still rise from there around 83,2% to KEUR 2,510 (Q3-2009: KEUR 1,370).

The segment „Healthcare service “lay with one total result after taxes of KEUR 358 (Q3 2009: KEUR 552) clearly under the previous year’s value, while the segment „Healthcare software“ with KEUR 2,152 (Q3 2009: KEUR 1,103) very clearly over that Prior year level lies. The result before taxes in third quarter amounted to KEUR 899 and lay thereby approximately 33 % over the previous year’s value (Q3 2009: KEUR 673). In relation to the previous year the operational cash flow increased by KEUR by 2.823 from KEUR 4,540 to KEUR 7,363 (+ 62.2 %).



The cash flow from investment activity amounts to of KEUR -5,052 after KEUR -1,961 (Q3-2009). The acquisition of a technology section by capital increase represents here apart from the disbursements for developments the substantial investment. The cash flow from financing activity amounted to KEUR 805 contained in it is the capital increase of 280.000 pieces, those to the acquisition that as well as technology section was used a repayment of commitments at values of KEUR 259.

**The liquid funds of the NEXUS-group rose because of the good result situation of EUR 11.5 million EUR to 14.9 million.**

The number of employees increased by 9 compared to the first half year 2010 to the current number of 373 (Q3 2009: 359). The increase in was mainly in the Healthcare Software area.



7



# NEXUS Group informationen and Outlook

## Directors Holdings

The Director's Holdings of the supervisory board and the executive board were as follows on September 30, 2010 in comparison to the previous year:

## Opportunities and Risks

The positive development during the current year is underpinned by a stable inflow of orders and an improved market position. Due to increasing demand and good acceptance of our system, we are foreseeing clear potential in the German CIS market, but also in the international markets. These potentials might materialise during the coming months. At the same time, there are considerable challenges from existing projects and development projects, which might jeopardise this trend. The same applies to new or existing competitors. We consider the integration of the acquired companies a particular continuing challenge. Here, we need to drive the technological and organisational integration forwards.

## Outlook

NEXUS has an unqualified positive position with a remarkable number of new orders, a high stock of orders on hand and again an improved quarterly result. Sales increases of 11% and an increase of the result before taxes of 50% are very pleasing results. We can also see in our cash flow and our increasing cash reserves that we do not have any deficits in other operational figures either.

We are going to continue this development in the current year and possibly even improve it. Maintaining these increase rates is a challenge, which we have to face. Our goal is to grow continuously and to present substantially increasing business figures.

This was our goal in past periods and remains the same today. We have worked intensively over the past years to set the foundation for long-term success. Today, we are very successful in the market with a lot of orders on hand and an excellent range of products.

However, we cannot sit back and be satisfied with our accomplishments at this point. It is a question of introducing additional innovations quickly into the market and to open up new markets for our products, especially in foreign countries. We still need to work on how fast we do this. This is critical for the success of our future development, and it will be a matter of working on this with all our might. The NEXUS staff has the will to success and commitment to invest the energy required to make these goals into a reality.

## ACCOUNTING AND VALUATION METHODS

This interim report from the NEXUS Group of 30 September 2010 has been prepared in keeping with the International Financial Reporting Standards (IFRS) as they are applied in the EU. The interpretation of the International Financial Reporting Interpretation Committee (IFRIC) has been taken into account.

The regulations of IAS 34 have been observed in the interim report of 30 September 2010. This refers to a summarized report, which does not contain all information of an IFRS Group Financial Statement, and consequently this report should be read in connection with the Appendix of the Group Financial Statement 2009. The same accounting and valuation methods were used in the Group Financial Statement for the business year 2009.

The report has not been audited.

The Group Financial Statement 2009 and the interim report of 30 September 2009 can be seen on the homepage in the Internet at: [www.nexus-ag.de](http://www.nexus-ag.de).

DIRECTORS HOLDINGS	NUMBER OF STOCKS OWNED	NUMBER OF OPTIONS
<b>SUPERVISORY BOARD</b>		
Dr. jur. Hans-Joachim König	81,099	0
	Prev. year: (81,099)	Prev. year: (0)
Prof. Dr. Alexander Pocsay	121,500	0
	Prev. year: (121,500)	Prev. year: (0)
Erwin Hauser	15,000	0
	Prev. year: (15,000)	Prev. year: (0)
Prof. Dr. Ulrich Krystek	0	0
	Prev. year: (0)	Prev. year: (0)
Dipl.-Betriebswirt (FH) Wolfgang Dörflinger	0	0
	Prev. year: (0)	Prev. year: (0)
Matthias Gaebler	0	0
	Prev. year: (0)	Prev. year: (0)
<b>EXECUTIVE BOARD</b>		
Dr. Ingo Behrendt (MBA)	112,000	325,000
	Prev. year: (112,000)	Prev. year: (325,000)
Ralf Heilig (MBA)	129,350	60,000
	Prev. year: (129,350)	Prev. year: (60,000)
Edgar Kuner (Dipl. Ingenieur)	264,051	37,000
	Prev. year: (264,051)	Prev. year: (37,000)

# Facts and Figures

## Group P+L Account as of 09/30/2010 and 09/30/2009 (IFRS)

CONSOLIDATED PROFIT AND LOSS ACCOUNT	07/01/ - 09/30/10	07/01/ - 09/30/09	01/01/ - 09/30/10	01/01/ - 09/30/09
	KEUR	KEUR	KEUR	KEUR
Revenue	11,429	10,202	32,160	29,030
Increase / decrease in finished goods and work in progress	-2	-3	-69	-34
Other capitalized company work	466	1,109	2,700	3,062
Other operating income	-703	207	1,033	1,647
Cost of materials	743	1,944	5,674	6,183
Personnel expenses	5,741	5,209	17,183	15,794
Depreciation and amortization of fixed intangible and tangible assets	1,404	1,414	6,499	3,978
Other operating expenses	2,311	2,341	4,008	6,347
<b>OPERATING INCOME</b>	<b>991</b>	<b>607</b>	<b>2,331</b>	<b>1,403</b>
Expenses from associated companies	0	0	0	0
Interest and similar income	-106	70	158	269
Interest payable and other similar charges	-14	4	13	17
<b>PROFIT BEFORE TAX</b>	<b>899</b>	<b>673</b>	<b>2,476</b>	<b>1,655</b>
Income taxes	-73	152	-34	285
<b>ANNUAL NET PROFIT</b>	<b>972</b>	<b>521</b>	<b>2,510</b>	<b>1,370</b>
Actuarial profits and losses (after taxes on profit)	-9	-4	-28	12
Differences from the conversion of foreign currency (after taxes on profit)	12	77	155	-1
Market value changes from assets available for sale (after taxes on profit)	37	173	89	320
<b>OTHER OVERALL RESULT</b>	<b>40</b>	<b>246</b>	<b>216</b>	<b>331</b>
<b>OVERALL RESULT OF THE PERIOD</b>	<b>1.012</b>	<b>767</b>	<b>2.726</b>	<b>1.701</b>
Of the period result, attributed to:				
- Stockholders of NEXUS AG	961	487	2.459	1.290
- Minority interests	11	34	51	80
Of the overall result, attributed to:				
- Stockholders of NEXUS AG	1.001	733	2.675	1.621
- Minority interests	11	34	51	80
<b>PERIOD RESULT PER SHARE IN EUR</b>				
Weighted average of issued shares in circulation (in thousand)	13.797	13.797	13.797	13.797
- simple	0,07	0,04	0,18	0,10
- diluted	0,07	0,04	0,18	0,10

# Facts and Figures

## Balance sheet as of 12/31/2009 and 09/30/2010 (IFRS)

10

BALANCE SHEET AS OF 09/30/2010 (IFRS)	09/30/2010	12/31/2009
	KEUR	KEUR
<b>LONG-TERM CAPITAL</b>		
Goodwill	12,304	11,642
Other Intangible assets	16,954	16,629
Fixed Assets	1,027	1,079
Investments in associates	98	98
Deferred taxes	2,657	2,496
Other financial assets	69	98
<b>TOTAL LONG-TERM CAPITAL</b>	<b>33,109</b>	<b>32,032</b>
<b>SHORT-TERM CAPITAL</b>		
Inventories	351	169
Raw materials and supplies and other arrears	12,208	12,588
Tax refund claims	155	350
Other non-financial debts	1,143	552
Other financial debts	1,787	1,577
Securities	2,107	1,981
Cash and cash equivalents	12,650	9,538
<b>TOTAL SHORT-TERM CAPITAL</b>	<b>30,401</b>	<b>26,755</b>
<b>TOTAL ASSETS</b>	<b>63,510</b>	<b>58,787</b>

# Facts and Figures

## Balance sheet as of 12/31/2009 and 09/30/2010 (IFRS)

BALANCE SHEET AS OF 09/30/2010 (IFRS) EQUITY AND LIABILITIES	09/30/2010	12/31/2009
	KEUR	KEUR
<b>CAPITAL AND RESERVE</b>		
Subscribed capital	14,085	13,805
Capital reserve	40,319	39,523
Net loss for the year	-3,438	-5,895
Other cumulated Group result	-391	-608
Own shares	-27	-26
<b>EQUITY CAPITAL ATTRIBUTABLE TO STOCKHOLDERS OF THE PARENT COMPANY</b>	<b>50,548</b>	<b>46,799</b>
Minority interest	407	243
<b>TOTAL EQUITY</b>	<b>50,955</b>	<b>47,042</b>
<b>LONG-TERM LIABILITIES</b>		
Pension provisions	706	610
Other provisions	1,295	1,018
<b>TOTAL LONG-TERM LIABILITIES</b>	<b>2,001</b>	<b>1,628</b>
<b>SHORT-TERM LIABILITIES</b>		
Deferments	1,635	776
Financial liabilities	31	290
Trade accounts payable	2,120	3,515
Liabilities from tax on profit	132	80
Deferred revenue liability	2,224	345
Other non-financial debts	1,778	2,257
Other financial debts	2,634	2,854
<b>TOTAL SHORT-TERM LIABILITIES</b>	<b>10,554</b>	<b>10,117</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>63,510</b>	<b>58,787</b>

<b>CASH FLOW</b>	<b>2010</b>	<b>2009</b>
	<b>KEUR</b>	<b>KEUR</b>
<b>1. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit before tax	2,509	1,655
Depreciation and amortization of intangible assets and plant, equipment and other fixed assets	4,137	3,978
Other expenses / income with no impact on cash	-106	-276
Depreciation of financial assets	-93	-107
Profit / loss from disposal of assets	0	0
Profit / loss from disposal of securities	0	136
Increase / decrease in trade receivables and other assets that cannot be allocated to investing or financing activities	-148	-2,965
Changes in provision	475	569
Increase / decrease in trade accounts payable and other liabilities that cannot be allocated to investing or financing activities	251	1,185
Interest paid	-13	-17
Interest payments received	176	265
Income taxes paid	-39	-118
Income taxes received	214	235
	<b>7,363</b>	<b>4,540</b>
<b>2. CASH FLOW FROM INVESTMENT ACTIVITIES</b>		
Cash paid for investments in property, plant and equipment / intangible assets	-4,005	-4,238
Cash receipt for investments in financial assets	0	0
Cash paid from disposal of fixed assets	0	0
Cash paid from purchase price adjustments at subsidiaries	0	0
Acquisition of consolidated companies, net of purchased cash	-1,020	-252
Cash receipts from disposal of securities	0	2,529
Cash paid for investments in securities	0	0
	<b>-1,961</b>	<b>-1,961</b>
<b>3. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Dividends paid to minority shareholders	280	0
Payments into equity capital via exercise of stock options	784	0
Purchase of own shares	0	0
Payments for taking loans within the context of short-term payment disposal	0	0
Amount paid/receipt out for redeeming/clearing loans	-259	-52
	<b>805</b>	<b>-52</b>
<b>4. CASH AND CASH EQUIVALENTS AT END OF FISCAL YEAR</b>		
Cash-relevant changes in cash and cash equivalents (sum of 1 + 2 + 3)	3,143	2,527
Change in currency translation adjustment	0	3
Consolidation circle-conditional change of financial funds	0	0
Cash and cash equivalents at beginning of fiscal year	9,538	4,141
	<b>12,681</b>	<b>6,671</b>
<b>5. COMPOSITION OF CASH AND CASH EQUIVALENTS</b>		
Cash on hand	12,650	6,730
Bank liabilities due on demand	31	-59
	<b>12,681</b>	<b>6,671</b>

# Facts and Figures Development

## of Group Equity as of 09/30/2010 and 09/30/2009 (IFRS)

### DEVELOPMENT OF GROUP EQUITY

	SUBSCRIBED CAPITAL	CAPITAL RESERVES	OTHER PROVISIONS	EQUITY DIFFERENCE FROM CURRENCY CONVERSION	RESERVE FOR FINANCIAL INSTRUMENTS	RESERVE FOR PENSIONS	CONSOLIDATED LOSS CARRY FORWARD	CONSOLIDATED DEFICIT / PROFIT	TREASURY STOCK	EQUITY CAP, ATTRIBUTABLE TO STOCKH, OF PARENT COMPANY	MINORITY INTEREST	TOTAL EQUITY	AUTHORIZED CAPITAL
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
<b>CONSOLIDATED EQUITY AS OF 12/31/2008</b>	13,805	39,483	0	59	-999	-72	-9,503	1,488	-26	44,235	259	44,494	6,860
Transfer of 2008 consolidated loss to consolidated loss carry-forward							1,488	-1,488		0		0	
Total income entered directly in equity capital			0	-4	320	12				328		328	
Profit before tax 09/30/2009								1,290		1,290	92	1,382	
<b>OVERAL RESULT OF THE PERIOD</b>	0	0	0	-4	320	12	0	1,290		1,618	92	1,710	
Stock-based payment		40								40		40	
<b>CONSOLIDATED EQUITY ON 09/30/2009</b>	13,805	39,523	0	55	-679	-60	-8,015	1,290	-26	45,893	351	46,244	6,860
<b>CONSOLIDATED EQUITY ON 12/31/2009</b>	13,805	39,523	0	59	-558	-109	-8,016	2,119	-26	46,799	243	47,042	6,860
Profit before tax 2009 entered directly in accumulated deficit							2,119	-2,119		0		0	
Allocation of authorised capital - AS 2010													43
Total income entered directly in equity capital				155	90	-27				215		215	
Capital increase to fixed assets	280	784								1,064		1,064	
Profit before tax 06/30/2010								2,458		2,458	164	2,622	
<b>OVERAL RESULT OF THE PERIOD</b>	0	0	0	155	90	-27	0	2,458		3,737	164	3,901	
Stock-based payment		12								12		12	
<b>CONSOLIDATED EQUITY ON 09/30/2010</b>	14,085	40,319	0	214	-468	-136	-5,897	2,458	-26	50,548	407	50,955	6,903

## **Declaration according to § 37y No. 1 WpHG**

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the group, and the interim management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group for the remaining months of the financial year.

Villingen-Schwenningen, November 8th, 2010

NEXUS AG  
Executive Board

**nexus/ag**

NEXUS AG, Auf der Steig 6, D-78052 Villingen-Schwenningen  
Telefon +49 (0)7721 8482 -0, Fax +49 (0)7721 8482-888  
[www.nexus-ag.de](http://www.nexus-ag.de), [info@nexus-ag.de](mailto:info@nexus-ag.de)